Skip to content

Study · Non-randomized trial · 2013

1 result

[The effectiveness of endonasal electrophoresis of neuroprotective agents used in the rehabilitative treatment of the patients presenting with primary open angle glaucoma].

Nazarova GA, Konchugova TV, Iurova OV, Sichinava NV, Turova EA, Rassulova MA, Morozova NE

Voprosy kurortologii, fizioterapii, i lechebnoi fizicheskoi kultury1 Nov 2013

PMID24640653 (opens in a new tab)PepBankPUB-24640653

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with primary open angle glaucoma, endonasal Cortexin electrophoresis produced greater positive clinical and test changes than intramuscular Cortexin.

    In plain wordsIn patients with glaucoma, endonasal Cortexin electrophoresis improved combined clinical and test measures more than intramuscular Cortexin.

    Outcome
    IncreaseClinical and functional examination changes
    Study

    n: not reported in source

    Comparator
    Intramuscular Cortexin
    Outcome group
    Vision and retina · Eye
    Studied dose
    Dose not stated · endonasal electrophoresisAs given in this study (human).

    Source sentences

    Summary
    It was shown that endonasal electrophoresis of cortexin resulted in more pronounced positive changes in the dynamics of clinical, functional, perimetric, and electrophysiological characteristics compared with intramuscular administration of the same drug to the patients of the control group.
    2 context sentences
    Summary · context
    This difference was apparent both immediately after the termination of the treatment and during the long-term follow-up.
    Summary · context
    The objective of the present study was to estimate the effectiveness of the peptide drug cortexin used to treat primary open angle glaucoma.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:25 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.